OUHSC Research News – Monday, May 29, 2023

International Ovarian Cancer Research Consortium in conjunction with the
International Society of Precision Cancer Medicine
Date: June 12 - 13, 2023 at the Omni Hotel in Oklahoma City

Description: The 2023 Meeting has been organized to provide a comprehensive overview of clinical challenges, research breakthroughs, and therapeutic innovations in two major thematic areas of cancer research, namely ovarian cancer and precision cancer medicine. This is an international conference consisting of distinguished speakers from Canada, China, India, Italy, Japan, Korea, Taiwan, Thailand, and USA with expertise in cancer biology, cancer genomics, targeted therapy, therapy resistance, personalized medicine, and cancer bioinformatics. Highly insightful papers will be presented in the form of keynote address, plenary lectures, and thematic sessions.
We will host a dinner on June 12 at the Oklahoma History Center, please RSVP at: https://ousurvey.qualtrics.com/jfe/form/SV_3n6TJfwiZzNiOFM  

Registration: https://ousurvey.qualtrics.com/jfe/form/SV_88LaN8tifTzNUN0

Contact: Emily Hulseberg  emily-hulseberg@ouhsc.edu

Office of Technology Commercialization presents the following opportunity for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).  

• AstraZeneca is seeking applicants from final year MD and/or PhD students or Postdoctoral Researchers within three years of receiving their advanced postgraduate degree for a fully funded post-doctoral position.  Proposal in should focus on innovative technologies to improve development of novel therapeutics and treatment approaches or be an innovative idea in one of AZ’’s focus areas (cardiovascular, renal and metabolic disease, respiratory and immunology, common infectious and rare diseases).  Successful candidates will be awarded a fully funded postdoctoral position.  Submission entails completion of non-confidential application. (deadline 06/30)   

• Updates to NIH Genomic Data Sharing Policy Institutional Certification Forms (NOT-OD-23-132)
• Updated Notice of Information for HIV research priorities at the National Heart, Lung, and Blood Institute (NOT-HL-23-088)

• Request for Information on Religion, Spirituality, and Alcohol Research Aims (NOT-AA-23-008)
• Notice of Change to Receipt Dates in RFA-AG-24-017, "Limited Competition: Renewal of the Longevity Consortium (U19 Clinical Trial Not Allowed)" (NOT-AG-23-025)

• Notice of Change to Application and Submission Information for RFA-NS-23-026 "BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed)" (NOT-NS-23-086)
• Notice of Intent to Publish a Notice of Funding Opportunity for the HEAL Initiative: KIDS Acute Pain Clinical Trials (APCT) Program (U01 Clinical Trial Required) (NOT-HD-23-015)

• Notice of Intent to Publish a Notice of Funding Opportunity for the HEAL Initiative: HEAL KIDS (Knowledge, Innovation and Discovery Studies) Pain Program Resource and Data Center (U24 Clinical Trial Not Allowed) (NOT-HD-23-016)
   
• Notice of Special Interest (NOSI): Administrative Supplement to Support the NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Research (NOT-CA-23-064)

• Notice of Special Interest (NOSI): Assessing Real-World Effectiveness and Implementation of Telehealth-Guided Provider-to-Provider Communication among Rural Communities
  (NOT-HL-23-083)

• Notice of Special Interest (NOSI): Competitive Revision Awards to National Institute on Minority Health and Health Disparities (NIMHD) Multiple Chronic Disease Centers for Emerging Therapeutic Interventions (NOT-MD-23-009)

• Notice of Special Interest (NOSI): Intersectional Stigma and Discrimination (ISD), or Other Social and Structural Determinants of Health (SSDOH) in HIV Prevention and Treatment (NOT-MH-23-270)

NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted).  The letters of intent will be reviewed and a single application will be chosen for submission from the University.

• Limited Competition: National Primate Research Centers (P51) (Clinical Trials Not Allowed) (PAR-23-126)
  Application Receipt Date(s): May 25, 2026
• Accelerating Behavioral and Social Science through Ontology Development and Use: Dissemination and Coordination Center (U24) Clinical Trial Not Allowed (PAR-23-181)
  Application Receipt Date(s): October 03, 2023
• Accelerating Behavioral and Social Science through Ontology Development and Use: Research Network Projects (U01 Clinical Trial Not Allowed) (PAR-23-182)
  Application Receipt Date(s): October 03, 2023
• Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01 Clinical Trial Not Allowed) (PAR-23-184)
  Application Receipt Date(s): July 08, 2026
• NEI Collaborative Clinical Vision Research Project: Resource Center Grant (UG1 Clinical Trial Required) (PAR-23-201)
  Application Receipt Date(s): May 25, 2026
• NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required) (PAR-23-204)
  Application Receipt Date(s): May 25, 2026
• NEI Collaborative Clinical Vision Research: Chair's Grant (UG1-Clinical Trial Required) (PAR-23-209)
  Application Receipt Date(s): Multiple dates, see announcement.
• Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed) (PAR-23-211)
  Application Receipt Date(s): October 04, 2023
• Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD and other ADRDs (R01 - Clinical Trial Not Allowed) (PAR-23-212)
  Application Receipt Date(s): October 04, 2023
• Specialized Alcohol Research Centers (P50 Clinical trial Optional) (RFA-AA-23-001)
  Application Receipt Date(s): November 15, 2023
• Comprehensive Alcohol Research Centers (P60 Clinical trial Optional) (RFA-AA-23-002)
  Application Receipt Date(s): November 15, 2023
• Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R41/R42 Clinical Trial Optional)
  (RFA-DA-24-017)
  Application Receipt Date(s): November 09, 2023
• Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R43/R44 Clinical Trial Optional)
  (RFA-DA-24-018)
  Application Receipt Date(s): November 10, 2023
• Limited Competition for the NIDDK Short-Term Research Experience Program to Unlock Potential (STEP-UP) (R25 Clinical Trial Not Allowed) (RFA-DK-22-510)
  Application Receipt Date(s): August 17, 2023
• NIMHD Centers of Excellence in Investigator Development and Community Engagement (P50 - Clinical Trial Optional) (RFA-MD-23-011)
  Application Receipt Date(s): August 04, 2023

Vilcek Foundation:  2024 Vilcek Prizes for Creative Promise in Biomedical Sciences

Description:  Immigrant biomedical researchers are encouraged to apply. Applicants must have been born outside the United States and be 38 years of age or younger, but limited exceptions to the age requirement may apply to individuals who have taken caregiving, medical, military, or parental leave. Three winners will each receivea $50,000 unrestricted cash prize and be honored at a reception in New York City in April 2024. 
Complete eligibility requirements and the online application can be found at www.vilcek.org.

Application Deadline: June 12, 2023

Link to Full Announcement: https://vilcek.org/prizes/vilcek-prizes-for-creative-promise/creative-promise-prizes-biomedical-science/?utm_source=salesforce&utm_medium=email&utm_campaign=2024cpp.biomed